SG11201504843UA - Non-replicating virus-derived particles and uses thereof - Google Patents

Non-replicating virus-derived particles and uses thereof

Info

Publication number
SG11201504843UA
SG11201504843UA SG11201504843UA SG11201504843UA SG11201504843UA SG 11201504843U A SG11201504843U A SG 11201504843UA SG 11201504843U A SG11201504843U A SG 11201504843UA SG 11201504843U A SG11201504843U A SG 11201504843UA SG 11201504843U A SG11201504843U A SG 11201504843UA
Authority
SG
Singapore
Prior art keywords
derived particles
replicating virus
replicating
virus
particles
Prior art date
Application number
SG11201504843UA
Other languages
English (en)
Inventor
David Conrad
Cory Batenchuk
Fabrice Leboeuf
John Cameron Bell
Original Assignee
Ottawa Hospital Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50977496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201504843U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ottawa Hospital Res Inst filed Critical Ottawa Hospital Res Inst
Publication of SG11201504843UA publication Critical patent/SG11201504843UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation
    • C12N2760/20263—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
SG11201504843UA 2012-12-21 2013-12-20 Non-replicating virus-derived particles and uses thereof SG11201504843UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261740856P 2012-12-21 2012-12-21
US201361835310P 2013-06-14 2013-06-14
PCT/CA2013/051009 WO2014094182A1 (en) 2012-12-21 2013-12-20 Non-replicating virus-derived particles and uses thereof

Publications (1)

Publication Number Publication Date
SG11201504843UA true SG11201504843UA (en) 2015-07-30

Family

ID=50977496

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201504843UA SG11201504843UA (en) 2012-12-21 2013-12-20 Non-replicating virus-derived particles and uses thereof
SG10201704903YA SG10201704903YA (en) 2012-12-21 2013-12-20 Non-replicating virus-derived particles and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201704903YA SG10201704903YA (en) 2012-12-21 2013-12-20 Non-replicating virus-derived particles and uses thereof

Country Status (17)

Country Link
US (2) US11110138B2 (https=)
EP (1) EP2935569B1 (https=)
JP (2) JP6612619B2 (https=)
KR (1) KR102167497B1 (https=)
CN (1) CN105121636A (https=)
AU (1) AU2013362761B2 (https=)
BR (1) BR112015015045A8 (https=)
CA (1) CA2896162C (https=)
CL (1) CL2015001738A1 (https=)
ES (1) ES2745599T3 (https=)
IL (1) IL239486B (https=)
MX (1) MX376266B (https=)
MY (1) MY174912A (https=)
PH (1) PH12015501442A1 (https=)
RU (1) RU2705556C2 (https=)
SG (2) SG11201504843UA (https=)
WO (1) WO2014094182A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014094182A1 (en) * 2012-12-21 2014-06-26 Ottawa Hospital Research Institute Non-replicating virus-derived particles and uses thereof
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
CN109985244A (zh) * 2017-12-29 2019-07-09 广州威溶特医药科技有限公司 E3连接酶抑制剂和溶瘤病毒在制备抗肿瘤药物的应用
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109432098B (zh) * 2018-11-20 2021-04-13 天津大学 化合物ps-341在制备小rna病毒科肠道病毒属病毒抑制剂的应用
EP3708176A1 (en) * 2019-03-15 2020-09-16 Centre National De La Recherche Scientifique -Cnrs- Mutant vsv ectodomain polypeptide and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106619A (en) 1983-12-20 1992-04-21 Diamond Scientific Co. Preparation of inactivated viral vaccines
HK1052950B (en) * 2000-06-26 2005-06-24 Wellstat Biologics Corporation Purging of cells using viruses
JP2005537802A (ja) 2002-09-09 2005-12-15 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション ラブドウイルスの組み換え型変異体及びその使用方法
JP4708027B2 (ja) * 2002-10-01 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗癌組成物および抗感染疾患組成物ならびにこれらを使用する方法
AU2003279770A1 (en) 2002-10-01 2004-04-23 Novartis Vaccines And Diagnostics, Inc. Anti-cancer and anti-infectious disease compositions and methods for using same
CN100579579C (zh) * 2002-10-01 2010-01-13 诺华疫苗和诊断公司 抗癌及抗感染性疾病组合物及其使用方法
DE602004018284D1 (de) 2003-03-27 2009-01-22 Ottawa Health Research Inst Mutante vesicular stomatitis viren und deren verwendungen
US7807176B2 (en) * 2004-03-19 2010-10-05 Genomidea, Inc. Polypeptide promoting vascular endothelial cell growth
US8703467B2 (en) * 2004-05-27 2014-04-22 Baxter International Inc. Inactivation of a pathogen in a sample by a treatment with formalin and UV light
CA2663034C (en) 2006-09-15 2016-05-03 Ottawa Health Research Institute Oncolytic rhabdovirus
JP5547640B2 (ja) * 2008-09-16 2014-07-16 ジェノミディア株式会社 前立腺癌の治療・予防剤
CA2836117C (en) * 2009-12-10 2017-08-15 Ottawa Hospital Research Institute Oncolytic rhabdovirus
US20130302368A1 (en) * 2011-01-27 2013-11-14 Boro Dropulic Advanced Prime and Boost Vaccine
CN103403594B (zh) * 2011-02-02 2016-11-23 康宁光缆系统有限责任公司 适用于为设备机架中的光学底板建立光学连接的稠密的光阀遮蔽的光纤连接器及总成
WO2012122649A1 (en) * 2011-03-15 2012-09-20 Ottawa Hospital Research Institute Recombinant orf virus
US9623096B2 (en) * 2011-11-09 2017-04-18 Celverum Inc. Virally infected hematopoietic cells and uses thereof
WO2014094182A1 (en) * 2012-12-21 2014-06-26 Ottawa Hospital Research Institute Non-replicating virus-derived particles and uses thereof

Also Published As

Publication number Publication date
CN105121636A (zh) 2015-12-02
US20210346441A1 (en) 2021-11-11
AU2013362761A1 (en) 2015-07-16
CA2896162C (en) 2021-10-12
JP2016501538A (ja) 2016-01-21
SG10201704903YA (en) 2017-07-28
US11110138B2 (en) 2021-09-07
CL2015001738A1 (es) 2015-12-18
IL239486B (en) 2019-08-29
NZ709439A (en) 2020-09-25
MX376266B (es) 2025-03-07
MY174912A (en) 2020-05-21
RU2015128766A (ru) 2017-01-26
EP2935569B1 (en) 2019-05-01
BR112015015045A8 (pt) 2018-01-23
JP6612619B2 (ja) 2019-11-27
CA2896162A1 (en) 2014-06-26
JP2020014467A (ja) 2020-01-30
RU2705556C2 (ru) 2019-11-07
MX2015008155A (es) 2016-02-05
KR102167497B1 (ko) 2020-10-20
EP2935569A4 (en) 2016-08-03
PH12015501442A1 (en) 2015-09-14
EP2935569A1 (en) 2015-10-28
AU2013362761B2 (en) 2019-08-01
WO2014094182A1 (en) 2014-06-26
US20150320810A1 (en) 2015-11-12
IL239486A0 (en) 2015-07-30
HK1210624A1 (en) 2016-04-29
ES2745599T3 (es) 2020-03-02
KR20150112957A (ko) 2015-10-07

Similar Documents

Publication Publication Date Title
IL256716A (en) Antibodies against hla–b*27 and their uses
ZA201500097B (en) Modified factor x polypeptides and uses thereof
SG11201408545RA (en) Polymer particles and use thereof
IL254416B (en) Anti-asic1 antibodies and their uses
SG11201500111VA (en) Peptides and uses thereof
GB2502167B (en) Vortex generator and applications thereof
IL237926A0 (en) Combinations and their uses
PL2745849T3 (pl) Kompozycja polideoksyrybonukleotydów i jej zastosowanie
ZA201405554B (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
SG11201501646PA (en) Peptides and their uses
EP2825548A4 (en) MODIFIED KISSPEPTIN PEPTIDES AND USES THEREOF
IL239486A0 (en) Non-replicating particles derived from viruses and their uses
SG11201504482VA (en) Beta-hexosyl-transferases and uses thereof
ZA201504462B (en) TGFß-DERIVED POLYPEPTIDES AND USES THEREOF
IL237400B (en) Rhizobacteria and its uses
GB201217832D0 (en) Fine particles
GB201208372D0 (en) Antibodies and uses thereof